DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02745470

CompletedPhase NA

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain Measured by Functional MRI

Asset

Lixisenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≤23•HbA1c ≤8.5%

Primary endpoints

•BOLD signal in hypothalamus•Whole brain connectivity

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02745470
Org study IDH-1507-038-686

Timeline

Milestones

Study first posted2016-04-20estimated
Last update posted2017-11-29actual
Study start2016-02 (month precision)
Primary completion2016-12actual (month precision)
Study completion2016-12actual (month precision)

Assets

Investigational agents

Lixisenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age19 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•BMI ≤ 23kg/m2 or BMI ≥ 26kg/m2
•participants with diabetes treated by diet or oral antidiabetic drug, HbA1c less than 8.5%

Exclusion criteria

•Those who diagnosed by Type 1 diabetes
•History of insulin therapy
•Aspartate aminotransferase(AST) or Alanine transaminase(ALT) >2.5 times of upper normal reference range
•Estimated Glomerular Filtration Rate(eGFR) <30 mL/min/1.73m2
•Those who can't be performed MRI

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Patient-reported / QoL
1
Other (unclassified)
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

mood change

Time frame:-30min, 45min(after fMRI), 70min(after buffet)

descriptive, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint/low confidence

Whole brain connectivity

Time frame:20min (50 min after injection)

descriptive

Secondary/protocol endpoint

appetite change

Time frame:-30min, 45min(after fMRI), 70min(after buffet)

change from baseline, improvement

Secondary/protocol endpoint

intake of food in the buffet

Time frame:50min

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Difference of BOLD (Blood oxygenation level-dependent) signal in hypothalamus

Time frame:10min (40 min after injection)

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.